ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Protocol ID
CDRB436G2201
Disease (Sub Disease)
Low grade glioma
High grade glioma
Diagnosis Stage
Relapse/refractory
Sponsor
Novartis Pharmaceuticals
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 17 Years
International registry ID's
NCT02684058
Back to Registry
Study Title Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Protocol ID CDRB436G2201
Disease (Sub Disease) Low grade glioma
High grade glioma
Diagnosis Stage Relapse/refractory
Sponsor Novartis Pharmaceuticals
Links https://clinicaltrials.gov/ct2/show/NCT02684058
Trial Status Closed to Recruitment
Trial Open Date 24/10/2017
Study Type Treatment
Phase Phase 2
Age Eligibility 12 Months to 17 Years
International registry ID's NCT02684058

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.